COMPANY SUMMARY BIO Boston 1x1 meeting GENKYOTEX ___________ NAME - PDF document

COMPANY SUMMARY BIO Boston 1x1 meeting GENKYOTEX ___________ NAME OF THE CEO Elias PAPATHEODOROU MISSION Genkyotex is a clinical stage biopharmaceutical company developing breakthrough NOX driven therapies. The Company is currently developing therapies for liver, kidney and lung fibrosis. TECHNOLOGY Its unique therapeutic approach is based on a selective inhibition of NOX enzymes that amplify multiple disease processes such as fibrosis, inflammation, pain processing, cancer development, and neurodegeneration. ALLIANCES/PARTNERSHIPS Serum institute of India Private Limited (SIIL) ADDRESS 218 av Marie Curie UPCOMING CATALYSTS Forum 2 Archamps Technopole 74166 Saint-Julien-en-Genevois Interim/Final results in a phase 2 clinical trial with GKT831 in PBC ____________________ MARKET FIGURES EMAIL info@genkyotex.com Revenues 2017:na Date of IPO:28.02.2017 www.genkyotex.com Ticker: GKTX Exchange: Euronext Paris and Brussels Currency: EUR MANAGEMENT TEAM Market cap: 116 MEUR CEO: Elias Papatheodorou Price: 1.5 EUR 52-weeks-high:2.55 EUR CFO: Alexandre Grassin 52-weeks-low:1.44 EUR CMO: Philippe Wiesel Average daily volume:94 K in 2018 ANALYST COVERAGE TARGETED MARKET ____________ Broker Date Reco. Target Price Potential (%) (buy/neutral/hol The fibrosis market spans across d) multiple indications in organs such Roth 16.01.2017 Buy 6.00 EUR +300% has the lung, the liver, the kidney, Oddo 27.10.2017 Buy 2.90 EUR +93% the eye and the skin. Fibrosis is Edisson 2017 - - - LifeSci 2017 - - - also implicated in oncology, it is Average: - - estimated that about 45% of all deaths in the developed world are SHAREHOLDERS related to fibrosis. Andera Partners: 23.76% LISTED COMPANY Eclosion 2 & Cie SCPC : 17.90% Vesalius Biocapital :8.88% Neomed: 7.27% CREATION DATE 2006

COMPANY SUMMARY BIO Boston 1x1 meeting GENKYOTEX ___________ NAME OF THE CEO Elias PAPATHEODOROU PIPELINE ADDRESS 218 av Marie Curie Forum 2 Archamps Technopole 74166 Saint-Julien-en-Genevois ____________________ EMAIL info@genkyotex.com www.genkyotex.com MANAGEMENT TEAM CEO: Elias Papatheodorou CFO: Alexandre Grassin CMO: Philippe Wiesel TARGETED MARKET ____________ The fibrosis market spans across multiple indications in organs such has the lung, the liver, the kidney, the eye and the skin. Fibrosis is also implicated in oncology, it is estimated that about 45% of all deaths in the developed world are related to fibrosis. LISTED COMPANY CREATION DATE 2006